A first-in-class monoclonal antibody for Zika, called Tyzivumab, is ready for human trials after only nine months of development, announced Tychan, a Singapore clinical-stage biotechnology company.
Tyzivumab targets the surface-exposed envelope (E) protein of the virus to stop it from fusing with host cells and prevent viral replication. It has been proven safe and effective in animals, according to Tychan in a media release.
The first patient dose will take place on Thursday, after getting the green light from Singapore's Health Sciences Authority. A total of 24 healthy volunteers will take part in Phase 1a of the clinical trial, said Tychan, adding that two more phases are likely to follow before the antibody is ready for patients’ use.